Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)